Navigation Links
Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice

r Research. The critical question is whether this approach would be safe and effective in smokers at high risk to develop lung cancer. Given that rapamycin is relatively inexpensive and FDA-approved for other indications, we are designing clinical trials in humans to address these questions and hope to have these answers in the near future.

Further research is needed to determine whether doses of rapamycin that achieve an anti-tumor effect in mice are similarly effective in humans, and whether giving a dose that would be sufficient for an anti-tumor effect would cause unacceptable levels of immune suppression or toxicity.

For more information on Dr. Denniss research, go to http://ccr.cancer.gov/Staff/Staff.asp?profileid=5727

For more information about cancer, please visit the NCI Web site at http://www.cancer.gov, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

--------------------------------------------------------------------------------
Reference: Granville C, Warfel N, Tsurutani J, Hollander C, Robertson M, Fox S, Veenstra T, Issaq H, Linnoila I, Dennis P. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity and phenotypic progression of tobacco carcinogen-induced murine lung tumors. C
'"/>




Page: 1 2 3 4

Related medicine technology :

1. GenoMed Prevents Sickle Cell Pain for Over a Year
2. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
5. Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study
6. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
Post Your Comments:
(Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
(Date:5/4/2015)... WORCESTER, Mass. and TORONTO ... ( www.generex.com ) (OTCQB:GNBT) today announced that it intends ... securities it receives upon completion of a definitive licensing ... to Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). ... a non-binding letter of intent in respect of the ...
(Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have their ... video and product demonstrations at the end of the ... such as Kodak and Fuji Cr,s, Agfa and Sony, ... the first event. Various imaging equipment will be available ... After years of buying and selling imaging ...
Breaking Medicine Technology:It's Better Hearing Month 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5RadiologyAuction Announces Event Starting On May 5th 2
... 16, Uroplasty, Inc. (Nasdaq: UPI ), ... innovative proprietary products to treat voiding dysfunctions, announced today ... Jiwani, Uroplasty,s Vice President and CFO, will present the ... Hunter Securities Inaugural Healthcare Conference at 3:30  PM PDT ...
... a crippling disease worldwide, with an estimated eight million sufferers ... a suit of rusty armour," with unrelenting, razor-like pain. ... reverse the degenerative condition. However a discovery made ... hold the key to not only halting the degenerative process, ...
Cached Medicine Technology:Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference 2New Hope For Joint Pain Sufferers 2New Hope For Joint Pain Sufferers 3
(Date:5/4/2015)... LiveSchool ” was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... students with good behavior. , Positive re-enforcement is more ... And the good people at LiveSchool have taken note ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The opportunity for ... full life are the motivating forces behind The Fairy Godmother ... psychologist and author Amy L. Stark. , The inspiration for ... girl next door comes from Stark’s desire to be a ... been a fairy godmother to my neighbors’ children since they ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The U.S. ... baby boomers join the ranks of senior citizens (1) ... on an already over-burdened healthcare system. Additionally, as older ... to replace them. Per the U.S. Census Bureau, the ... to increase 75% by 2050 while those 25 to ...
(Date:5/4/2015)... OK and Seattle, WA (PRWEB) May 04, 2015 ... the formation of a collaboration to facilitate development of ... of ophthalmic disorders that lead to blindness, including Diabetic ... the MiDROPS™ formulation platform developed by EyeCRO, which can ... eye via a topical eyedrop. , Under the ...
(Date:5/4/2015)... 04, 2015 New findings released today ... Association (ABTA) show that people diagnosed with a brain ... options, including clinical trials, at the time of diagnosis, ... difficult decisions about their course of treatment. The release ... first nationwide brain tumor volunteer network, the ABTA CommYOUnity™, ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... Highlights, - Revenue for the first quarter was $480.6 million, up 7.6% from ... ... ("FOI") grew 7.2% for the twelve, months ended March 31, 2008 over ... was $38.6 million, or $0.38,per outstanding common share, a 19% increase over the ...
... project as innovative in terms of energy efficiency and ... awarded nearly $27 million in funding for a new ... (USC). USC was one of 12 California institutions considered ... million to build stem cell research facilities throughout California. ...
... May 8, 2008 at 2:00 pm ET, MISSION ... ENSG ), the parent company of the Ensign(TM) ... today reported results for the first quarter of fiscal ... ) Highlights of the First Quarter Include:, ...
... 7 Conseco, Inc. (NYSE: CNO ),today reported ... set a new quarterly sales record with an increase ... Prieur said. "This performance included,an 11% increase at Bankers ... increase in total sales including new product offerings) of ...
... , Ottawa (May 7, 2008) The Honourable ... the Canadian Institutes of Health Research (CIHR) for 764 ... Minister Clement was joined by Dr. Patrick McGrath, a ... neonatologist and CIHR-funded researcher from the University of Alberta, ...
... 7 Dr. Hugo Stephenson, founder and ... drug safety, today,presented new insight about the ... the U.S. Food and Drug Administration (FDA). ... (rosuvastatin),Lipitor (atorvastatin), and Zocor (simvastatin) all warn ...
Cached Medicine News:Health News:Brookdale Announces First Quarter 2008 Results 2Health News:Brookdale Announces First Quarter 2008 Results 3Health News:Brookdale Announces First Quarter 2008 Results 4Health News:Brookdale Announces First Quarter 2008 Results 5Health News:Brookdale Announces First Quarter 2008 Results 6Health News:Brookdale Announces First Quarter 2008 Results 7Health News:Brookdale Announces First Quarter 2008 Results 8Health News:Brookdale Announces First Quarter 2008 Results 9Health News:Brookdale Announces First Quarter 2008 Results 10Health News:Brookdale Announces First Quarter 2008 Results 11Health News:Brookdale Announces First Quarter 2008 Results 12Health News:Brookdale Announces First Quarter 2008 Results 13Health News:Brookdale Announces First Quarter 2008 Results 14Health News:Brookdale Announces First Quarter 2008 Results 15Health News:Brookdale Announces First Quarter 2008 Results 16Health News:Brookdale Announces First Quarter 2008 Results 17Health News:Brookdale Announces First Quarter 2008 Results 18Health News:Brookdale Announces First Quarter 2008 Results 19Health News:Brookdale Announces First Quarter 2008 Results 20Health News:Brookdale Announces First Quarter 2008 Results 21Health News:Brookdale Announces First Quarter 2008 Results 22Health News:USC receives nearly $27 million in funding for new stem cell research facility 2Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 2Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 3Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 4Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 5Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 6Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 7Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 8Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 9Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 10Health News:Conseco Reports First Quarter Results 2Health News:Conseco Reports First Quarter Results 3Health News:Conseco Reports First Quarter Results 4Health News:Conseco Reports First Quarter Results 5
Pocket-sized instrument, powered by two AA-sized alkaline batteries. Built-in throat illuminator, rectangular viewing lens for instrumentation under magnification....
The Pneumatic Consulting Otoscope provides two viewing lenses for dual observation of the tympanic membrane. Sealed system for pneumnatic otoscopy and rotatable head for left- and right-sided viewin...
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
... to laser treatment of AMD patients ... compares to the Opal Photoactivator from,Lumenis. ... (verteporfin for injection) therapy, the Opal ... any other laserfeatures,that ensure the highest ...
Medicine Products: